Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Integra Lifesciences Holdings (IART) Total Liabilities (2016 - 2025)

Historic Total Liabilities for Integra Lifesciences Holdings (IART) over the last 17 years, with Q3 2025 value amounting to $2.6 billion.

  • Integra Lifesciences Holdings' Total Liabilities rose 254.15% to $2.6 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $2.6 billion, marking a year-over-year increase of 254.15%. This contributed to the annual value of $2.5 billion for FY2024, which is 1358.37% up from last year.
  • Integra Lifesciences Holdings' Total Liabilities amounted to $2.6 billion in Q3 2025, which was up 254.15% from $2.6 billion recorded in Q2 2025.
  • In the past 5 years, Integra Lifesciences Holdings' Total Liabilities registered a high of $2.6 billion during Q2 2025, and its lowest value of $2.1 billion during Q1 2022.
  • Over the past 5 years, Integra Lifesciences Holdings' median Total Liabilities value was $2.2 billion (recorded in 2023), while the average stood at $2.3 billion.
  • As far as peak fluctuations go, Integra Lifesciences Holdings' Total Liabilities tumbled by 702.56% in 2022, and later skyrocketed by 2128.77% in 2024.
  • Integra Lifesciences Holdings' Total Liabilities (Quarter) stood at $2.1 billion in 2021, then decreased by 0.58% to $2.1 billion in 2022, then rose by 5.21% to $2.2 billion in 2023, then increased by 13.58% to $2.5 billion in 2024, then grew by 4.68% to $2.6 billion in 2025.
  • Its last three reported values are $2.6 billion in Q3 2025, $2.6 billion for Q2 2025, and $2.5 billion during Q1 2025.